Study: Establishing Methods for Evaluating Anti-tumor Therapies for Treatment of Pseudomyxoma Peritonei (PMP) using Gene Profiles and Immortalized Cells
Andrew G. Renehan, PhD
School of Cancer and Enabling Sciences
University of Manchester, UK

The Manchester (UK) group is the first worldwide group to successfully culture cells directly from patients with pseudomyxoma peritonei.

We have used DNA fingerprinting to demonstrate that these cells are from the original patients. We have undertaken gene analyses to show that a range of genes relevant for tumor growth are either increased or decreased, and confirmed these changes to be true in the samples from patients. Importantly, for the first time, our team can now test conventional and novel drugs in the laboratory. The success of this project has been supported by NORD (with funding by the PMP Research Foundation) and enabled through the centralized treatment of PMP in the UK.